Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma

• Published in: Cancers Vol. 12; no. 4; p. 1027
• Main Authors: Amaral, Teresa, Seeber, Olivia, Mersi, Edgar, Sanchez, Stephanie, Thomas, Ioannis, Meiwes, Andreas, Forschner, Andrea, Leiter, Ulrike, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22-04-2020; MDPI
• Subjects: Antigen presentation; Disease control; Immune checkpoint inhibitors; Immunoglobulins; Immunotherapy; Localization; Melanoma; Metastasis; Multivariate analysis; Mutation; PD-1 protein; Proteins; Regression analysis; Risk factors; Risk groups; S100b protein; Skin cancer; Statistical analysis; United States > US; pseudoprogression; primary resistance; checkpoint-inhibitors; combined immunotherapy; metastatic melanoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers12041027

Primary resistance to immunotherapy can be observed in approximately 40-65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of the patients receive a second-line therapy, and the clinical benefit is small.
Stage IV melanoma patients treated with first-line PD-1-based immunotherapy between January 2015 and December 2018 were investigated. Primary resistance was defined as progressive disease (PD) at the time of the first tumor assessment after starting immunotherapy. Patients with complete response, partial response, and stable disease were classified as having disease control (DC). Overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier estimator. Univariate and multivariate logistic regression analyses were performed to determine prognostic factors associated with OS.
Three hundred and nineteen patients were included, and 40% had primary resistance to immunotherapy. The median follow-up time was 22 months. Patients with primary resistance had 1-, 2-, and 3-year OS rates of 41%, 15%, and 10%, respectively, compared to 91%, 81%, and 65% for the patients who achieved DC. The following independently significant prognostic factors for OS were identified: protein S100B level and primary tumor localization. There was a statistically significant difference for OS (
< 0.0001) but not for PFS (
= 0.230) when analyzing risk groups formed with a combination of these two variables (low-, intermediate-, and high-risk subgroups).
Melanoma patients with primary resistance to immunotherapy have a dismal prognosis. Response at the first tumor assessment after starting immunotherapy is a stronger prognostic factor for the further course of the disease than pretreatment risk factors.